Cereno Scientific announced that an abstract on the preclinical drug candidate, novel IP receptor agonist CS585, was presented at the EHA 2024 Hybrid Congress, in Madrid, June 15th, 2024. The abstract titled "Superior Selectivity of CS585 to The Prostacyclin Receptor Translates to A New Viable Target for Prevention of Thrombosis", was authored by L. Stanger, P Yalavarthi, A. Rickenberg, K. Goerger, D. Gilmore and M. Holinstat, at University of Michigan, Ann Arbor, USA; and B. Dahlof, Cereno Scientific, Gothenburg, Sweden. The abstract was presented by Livia Stanger, from the Holinstat Lab at University of Michigan, led by Dr. Michael Holinstat, Professor at the Department of Pharmacology, the Department of Internal Medicine (Division of Cardiovascular Medicine), and the Department of Vascular Surgery at the University of Michigan.

Dr. Holinstat leads Cereno's discovery programs at the University of Michigan and is Director of Translational Research at Cereno. Drug candidate CS585 is a highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding.

A license agreement for drug candidate CS585 with the University of Michigan provides Cereno Scientific exclusive rights to further development and commercialization of CS585. In early November 2023, CS585 was highlighted by top-tier medical journal Blood as a promising novel anti-thrombotic strategy without risk of bleeding.